| Literature DB >> 34099809 |
Yoo-Jin Bang1,2, So-Hee Hong1,2, Hyo-Jung Park1,2, Hye Won Kwak1,2, Yu-Sun Lee1,2, Jae-Yong Kim1,2, Hyeong-Jun Park1,2, Seo-Hyeon Bae1,2, Hye-Jung Kim1, Yun-Hee Kim3, Hae Li Ko4, Sang-In Park4, Hun Kim3, Gyeongjoo Park5, Man-Seong Park6, Jun Chang5, Jae-Hwan Nam7,8.
Abstract
There is an unmet need for new influenza vaccine strategies that compensate for impaired vaccine responses in elderly individuals. Here, we evaluated the effectiveness of a single-stranded RNA (ssRNA) as an adjuvant to enhance the efficacy of inactivated influenza vaccine (IIV) in mouse models. Immunization with the ssRNA along with IIV reduced viral titers as well as pathological and inflammatory scores in the lungs after influenza challenge in aged mice. ssRNA induced balanced Th1/Th2 responses with an increase in IgA titers. Moreover, the ssRNA adjuvant markedly increased the frequency of influenza HA-specific T cells and IFN-γ production along with the expression of genes related to innate and adaptive immune systems that could overcome immunosenescence in aged mice. Our findings indicate that ssRNA is an efficient vaccine adjuvant that boosts cellular and humoral immunity in aged mice, demonstrating its potential as a novel adjuvant for currently available influenza virus vaccines for elderly individuals.Entities:
Year: 2021 PMID: 34099809 DOI: 10.1038/s41598-021-91445-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379